Barchart on MSN

Amgen stock: Is AMGN outperforming the healthcare sector?

With a market cap of $181.8 billion, Amgen Inc. (AMGN) is a global biotechnology company that discovers, develops, ...
Zacks Investment Research on MSN

Here's why Amgen (AMGN) is a strong momentum stock

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. Featuring daily updates ...

AMGN Stock Down 13% in 3 Months: Buy the Dip or Book Profits?

Amgen faces LOE headwinds and pricing pressure, yet key growth drugs and biosimilars continue gaining traction.

Amgen's Growth Engine Is Just Getting Started

Amgen delivers consistent, market-beating returns, supported by a robust growth portfolio and prudent capital allocation.
Insider Monkey

Amgen (AMGN) Stock Up Since Jim Cramer Said “You Could Do a Lot Worse Than Amgen”

Amgen Inc. (NASDAQ:AMGN) is one of Jim Cramer’s Hottest GLP-1 and Weight Loss Stock Picks. Amgen Inc. (NASDAQ:AMGN) is one of the largest drug companies in the world. The firm is currently developing ...
Forbes

What’s Happening With Amgen Stock?

14 January 2025, Bavaria, Munich: The company logo and the lettering of the biotechnology company Amgen can be seen on the facade of the company's headquarters in Munich (Bavaria) on January 14, 2025.

Guggenheim Trims Amgen Price Target to $340: Is the Biotech Giant Losing Its Edge?

Guggenheim trimmed its price target (PT) on Amgen (NASDAQ:AMGN) to $340 from $351 on Monday, May 4, while maintaining a Neutral rating. The revision follows the biotech’s Q1 2026 earnings release and ...